AstraZeneca and Severance Hospital in Korea Sign Partnership to Strengthen Cooperation in Clinical Trials
May 22, 2025
|
This is to create an environment in which high-quality clinical trials can be carried out in a timely and efficient manner and to provide innovative treatment opportunities for patients with chronic diseases, rare diseases, and cancer.
Under this agreement, AstraZeneca Korea will share clinical development plans for existing and future development portfolios with Severance Hospital and design optimized implementation plans to ensure that clinical trials operate smoothly in a timely manner.Through this, it is expected to more smoothly conduct high-level clinical trials for new drugs such as CAR-T (chimeric antigen receptor T cell) treatments in Korea, providing patients with limited treatment options with innovative treatment opportunities at a faster time, increasing their access to treatment.
Jeon Se-hwan, CEO of AstraZeneca Korea, said, "Korea AstraZeneca is striving to create a patient-centered healthcare ecosystem based on the corporate value of "We Put Patients First"."As part of this partnership with Severance Hospital, we will continue to cooperate with the domestic medical community to deliver innovative treatment solutions to patients faster."
"The strategic partnership with AstraZeneca Korea will be an important opportunity to take the domestic clinical trial environment and access to innovative treatments to the next level," said Lee Kang-young, director of Severance Hospital.
This article was translated by Naver AI translator.
